HK1212270A1 - Tripterygium wilfordii extracts to overcome chemotherapy resistance - Google Patents

Tripterygium wilfordii extracts to overcome chemotherapy resistance Download PDF

Info

Publication number
HK1212270A1
HK1212270A1 HK15112587.7A HK15112587A HK1212270A1 HK 1212270 A1 HK1212270 A1 HK 1212270A1 HK 15112587 A HK15112587 A HK 15112587A HK 1212270 A1 HK1212270 A1 HK 1212270A1
Authority
HK
Hong Kong
Prior art keywords
docetaxel
cells
lgt
cancer
treatment
Prior art date
Application number
HK15112587.7A
Other languages
English (en)
Chinese (zh)
Inventor
莫塞斯．辛．薩姆．喬
莫塞斯．辛．萨姆．乔
黃英
黄英
王競華
王竞华
拉納德希爾‧拉武拉
拉纳德希尔‧拉武拉
汪志軍
汪志军
Original Assignee
健康科学西部大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 健康科学西部大学 filed Critical 健康科学西部大学
Publication of HK1212270A1 publication Critical patent/HK1212270A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK15112587.7A 2012-08-19 2013-08-19 Tripterygium wilfordii extracts to overcome chemotherapy resistance HK1212270A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261684792P 2012-08-19 2012-08-19
US61/684,792 2012-08-19
PCT/US2013/055602 WO2014031543A1 (en) 2012-08-19 2013-08-19 Tripterygium wilfordii extracts to overcome chemotherapy resistance

Publications (1)

Publication Number Publication Date
HK1212270A1 true HK1212270A1 (en) 2016-06-10

Family

ID=50150329

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15112784.8A HK1211888A1 (en) 2012-08-19 2013-08-19 Tripterygium wilfordii extracts to overcome chemotherapy resistance
HK15112587.7A HK1212270A1 (en) 2012-08-19 2013-08-19 Tripterygium wilfordii extracts to overcome chemotherapy resistance

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK15112784.8A HK1211888A1 (en) 2012-08-19 2013-08-19 Tripterygium wilfordii extracts to overcome chemotherapy resistance

Country Status (9)

Country Link
US (1) US10149876B2 (enExample)
EP (1) EP2888011A4 (enExample)
JP (1) JP6367801B2 (enExample)
CN (1) CN104797296B (enExample)
AU (2) AU2013306058A1 (enExample)
CA (1) CA2880575C (enExample)
HK (2) HK1211888A1 (enExample)
IN (1) IN2015DN01496A (enExample)
WO (1) WO2014031543A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014318623C1 (en) * 2013-09-13 2019-10-24 Western University Of Health Sciences Wilforlide A for overcoming chemotherapy resistance
CN111909119B (zh) * 2020-08-25 2023-06-16 上海诗丹德标准技术服务有限公司 雷公藤来源化合物及其应用和制备方法、药物组合物、杀虫剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7570191A (en) * 1990-03-14 1991-10-10 Board Of Regents, The University Of Texas System Tripterygium wilfordii hook f extracts and components thereof for immunosuppression
JPWO2004075888A1 (ja) 2003-02-27 2006-06-01 輝夫 西田 角膜潰瘍治療剤
CN102443039B (zh) * 2010-10-14 2013-11-13 中国科学院上海药物研究所 N-取代氨基苯基-14β-氨甲基表雷公藤内酯醇衍生物及其制备方法和用途

Also Published As

Publication number Publication date
CA2880575C (en) 2023-07-11
US20150238553A1 (en) 2015-08-27
EP2888011A1 (en) 2015-07-01
EP2888011A4 (en) 2016-01-27
IN2015DN01496A (enExample) 2015-07-03
AU2018200709B2 (en) 2019-10-24
JP6367801B2 (ja) 2018-08-01
AU2013306058A1 (en) 2015-02-19
US10149876B2 (en) 2018-12-11
WO2014031543A1 (en) 2014-02-27
CN104797296B (zh) 2019-12-17
JP2015529664A (ja) 2015-10-08
AU2018200709A1 (en) 2018-02-22
HK1211888A1 (en) 2016-06-03
CA2880575A1 (en) 2014-02-27
CN104797296A (zh) 2015-07-22

Similar Documents

Publication Publication Date Title
Suberu et al. Comparative cytotoxicity of artemisinin and cisplatin and their interactions with chlorogenic acids in MCF7 breast cancer cells
Yang et al. Enhanced oral bioavailability and anti‐tumour effect of paclitaxel by 20 (s)‐ginsenoside Rg3 in vivo
WO2019222459A1 (en) Cannabinoid preparations and therapeutic uses
Chanmahasathien et al. Stemona alkaloids, from traditional Thai medicine, increase chemosensitivity via P-glycoprotein-mediated multidrug resistance
US12251411B2 (en) Methods of treating endometrial cancer using hemp extract
Han et al. Guizhi Fuling Wan, a Traditional Chinese Herbal Formula, Sensitizes Cisplatin‐Resistant Human Ovarian Cancer Cells through Inactivation of the PI3K/AKT/mTOR Pathway
JP2019123728A (ja) 化学療法耐性を克服するためのウィルホルリドａの使用
Lü et al. Oriental herbs as a source of novel anti-androgen and prostate cancer chemopreventive agents
Chen et al. Identification of arnicolide C as a novel chemosensitizer to suppress mTOR/E2F1/FANCD2 axis in non‐small cell lung cancer
AU2018200709B2 (en) Tripterygium wilfordii extracts to overcome chemotherapy resistance
Hidayat et al. Phytochemical analysis and in vitro cytotoxicity test of black soybean (Glycine soja L.) ethanolic extract as a growth inhibitor of the HCT-116 colon carcinoma cell line
Bhutta et al. Phytochemicals as Novel Therapeutics for Triple‐Negative Breast Cancer: A Comprehensive Review of Current Knowledge
Agarwal et al. Standardized fraction of Xylocarpus moluccensis inhibits inflammation by modulating MAPK-NFκB and ROS-HIF1α-PKM2 activation
Li et al. Overcome multidrug resistance in colorectal cancer by natural compounds
WANANDI et al. ADDITIVE CYTOTOXIC EFFECT OF CISPLATIN AND ANDROGRAPHIS PANICULATA EXTRACT THROUGH THE MODULATION OF APOPTOTIC MARKERS, CYCLIN-D AND VEGF EXPRESSIONS IN SKOV3 OVARIAN CANCER CELL LINE
Dweh et al. Phytochemicals as Radioprotective and Radiosensitizing Agents in Cancer Radiotherapy: Advances, Challenges, and Future Perspectives
EP1549330B1 (en) Pomolic acid for treating multidrug resistant tumours
HK1225677B (en) Use of wilforlide a for overcoming chemotherapy resistance